Showing results (51-60 of 69) with videos related to
Sort By:
Pageof 7
The AAPS Journal|June 16, 2010
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technologyClaudia Fredolini, Francesco Meani, Alessandra Luchini, et al.Cancer Letters|December 27, 2016
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohortsPaola Todeschini, Elisa Salviato, Lara Paracchini, et al.International Journal of Cancer|February 26, 2020
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancerGiuseppe Benvenuto, Paola Todeschini, Lara Paracchini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric StudyPaolo Martini, Lara Paracchini, Giulia Caratti, et al.Cancers|June 2, 2021
Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic TargetsChiara Romani, Eliana Bignotti, Davide Mattavelli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2013
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificitiesEnrica Calura, Robert Fruscio, Lara Paracchini, et al.Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.Plos One|November 6, 2009
Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patientsBih-Rong Wei, Shelley B Hoover, Mark M Ross, et al.Journal for Immunotherapy of Cancer|October 8, 2021
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, K Alex Hodge, Guido Bellezza, et al.Gynecologic Oncology|November 30, 2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroStefania Bellone, Eliana Bignotti, Silvia Lonardi, et al.Pageof 7